Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Current Deferred Revenue (2019 - 2025)

Pulmonx (LUNG) has disclosed Current Deferred Revenue for 7 consecutive years, with $100000.0 as the latest value for Q3 2025.

  • Quarterly Current Deferred Revenue fell 8.26% to $100000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $100000.0 through Sep 2025, down 8.26% year-over-year, with the annual reading at $135000.0 for FY2024, 29.81% up from the prior year.
  • Current Deferred Revenue for Q3 2025 was $100000.0 at Pulmonx, up from $78000.0 in the prior quarter.
  • The five-year high for Current Deferred Revenue was $200000.0 in Q3 2021, with the low at $75000.0 in Q1 2021.
  • Average Current Deferred Revenue over 5 years is $114000.0, with a median of $104000.0 recorded in 2023.
  • The sharpest move saw Current Deferred Revenue surged 100.0% in 2021, then plummeted 50.0% in 2022.
  • Over 5 years, Current Deferred Revenue stood at $200000.0 in 2021, then tumbled by 50.0% to $100000.0 in 2022, then rose by 4.0% to $104000.0 in 2023, then grew by 29.81% to $135000.0 in 2024, then fell by 25.93% to $100000.0 in 2025.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $100000.0, $78000.0, and $128000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.